Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Download Publication
28 Jan 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

6 Nov 2023

Nasal Inhalation Testing: IPAC-RS Droplet Size Analysis

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
13 Oct 2023

Nasal Drug Delivery: In Vitro Anatomical Models

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
4 Aug 2023

Aptar Pharma Discusses Intranasal Drug Delivery with PharmTech

Podcasts, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
3 Jul 2023

Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 22
Back To Top